Details werden geladen...
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China | The Manila Times
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
Ähnliche Seiten
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China | The Manila Times
https://www.manilatimes.net/2026/06/08/tmt-newswire/pr-newswire/everest-medicines-enters-into-asset-purchase-agreement-with-corxel-pharmaceuticals-to-develop-and-commercialize-lnz100-in-greater-china/2360321Knight Therapeutics Announces Launch of TAVALISSE® in Mexico | The Manila Times
https://www.manilatimes.net/2026/05/28/tmt-newswire/globenewswire/knight-therapeutics-announces-launch-of-tavalisse-in-mexico/2353197Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/rakovina-therapeutics-announces-q1-2026-financial-results-and-provides-corporate-update/2356285Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/axsome-therapeutics-announces-settlement-resolving-all-sunosi-solriamfetol-patent-litigation/2357679Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/pr-newswire/nuance-pharma-announces-ind-clearance-for-actair-pivotal-clinical-trial-in-china/2349777